ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
  • Abstract Number: 0610

    Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
  • Abstract Number: 0611

    Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study
  • Abstract Number: 0612

    Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
  • Abstract Number: 0613

    Prediction of Spontaneous Abortion in Women with Systemic Lupus Erythematosus (SLE) Based on Machine Learning Model: Insights from the Egyptian College of Rheumatology (ECR)–SLE Cohort
  • Abstract Number: 0614

    Bridging the Gap Between Patient’s Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient
  • Abstract Number: 0615

    Socioeconomic Determinants of Lupus Hospitalization Outcomes: A Review of Current Knowledge and Analysis of the 2016-2019 NRD Database
  • Abstract Number: 0616

    Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus
  • Abstract Number: 0617

    Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation
  • Abstract Number: 0618

    Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls
  • Abstract Number: 0619

    Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
  • Abstract Number: 0620

    Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
  • Abstract Number: 0621

    Predictive Parameters of Disease-related Damage Accrual in Patients with Systemic Lupus Erythematosus: A Machine Learning Analysis
  • Abstract Number: 0622

    Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre
  • Abstract Number: 0623

    Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
  • Abstract Number: 0624

    Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients with Lupus Nephritis
  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 182
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology